Optimization of Preemptive Therapy for Cytomegalovirus Infections With Valganciclovir Based on Therapeutic Drug Monitoring: Protocol for a Phase II, Single-Center, Single-Arm Trial
BackgroundValganciclovir (VGCV) is the first-line drug for preemptive therapy of cytomegalovirus (CMV) infections. However, even when administered at the dose specified in the package insert, there is significant interindividual variability in the plasma concentrations of gan...
Saved in:
| Main Authors: | Naoki Tamura, Kotaro Itohara, Yo Ueda, Yumi Kitahiro, Kazuhiro Yamamoto, Tomohiro Omura, Toshiyasu Sakane, Jun Saegusa, Ikuko Yano |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
JMIR Publications
2025-06-01
|
| Series: | JMIR Research Protocols |
| Online Access: | https://www.researchprotocols.org/2025/1/e72549 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Neonatal metabolic alkalosis and mild diuresis resulting from torasemide self-medication by the mother: a case report
by: Yumi Kitahiro, et al.
Published: (2025-04-01) -
Changes in Neutrophil Count During Valganciclovir Therapy for Symptomatic Congenital Cytomegalovirus Infection
by: Aoi Kawamura, et al.
Published: (2025-07-01) -
Cost-utility and budget impact analyses of valganciclovir for cytomegalovirus retinitis in patients with human immunodeficiency virus in Thailand
by: Tippawan Wongwian, et al.
Published: (2025-12-01) -
Valacyclovir versus valganciclovir for cytomegalovirus prophylaxis in kidney transplant recipients: a systematic review and comparative meta-analysis
by: Leonardo Januário Campos Cardoso, et al.
Published: (2025-03-01) -
Transient Azoospermia Induced by Valganciclovir Treatment for Cytomegalovirus Infection in a Reproductive Male After Kidney Transplant: A Case Report
by: Kosuke Mieda, et al.
Published: (2025-07-01)